全文获取类型
收费全文 | 225篇 |
免费 | 16篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 1篇 |
妇产科学 | 4篇 |
基础医学 | 12篇 |
口腔科学 | 1篇 |
临床医学 | 6篇 |
内科学 | 79篇 |
皮肤病学 | 1篇 |
神经病学 | 35篇 |
特种医学 | 2篇 |
外科学 | 27篇 |
一般理论 | 1篇 |
预防医学 | 4篇 |
眼科学 | 1篇 |
药学 | 8篇 |
肿瘤学 | 58篇 |
出版年
2022年 | 2篇 |
2021年 | 4篇 |
2020年 | 2篇 |
2019年 | 2篇 |
2018年 | 4篇 |
2017年 | 6篇 |
2016年 | 9篇 |
2015年 | 6篇 |
2014年 | 13篇 |
2013年 | 19篇 |
2012年 | 20篇 |
2011年 | 28篇 |
2010年 | 7篇 |
2009年 | 17篇 |
2008年 | 12篇 |
2007年 | 16篇 |
2006年 | 11篇 |
2005年 | 16篇 |
2004年 | 10篇 |
2003年 | 5篇 |
2002年 | 7篇 |
2001年 | 5篇 |
2000年 | 3篇 |
1999年 | 3篇 |
1998年 | 2篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 2篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1981年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有241条查询结果,搜索用时 15 毫秒
21.
Giagounidis AA Beckmann MW Giagounidis AS Aivado M Emde T Germing U Riehs T Heyll A Aul C 《European journal of haematology》2000,65(4):267-271
In acute promyelocytic leukemia (APL), the use of all-trans-retinoic acid (ATRA) as a differentiating agent induces complete remission in a high percentage of patients. In pregnancy, however, this drug bears the risk of severe teratogenicity to the child. We report the case of a 23-yr-old woman at 21 weeks' gestation suffering from APL. She was treated with ATRA (45 mg/m2) for 40 d and two courses of standard chemotherapy. The mother achieved complete remission within 22 d of treatment. Fetal development was normal, and a healthy premature girl was born in the 35th week of pregnancy. In a review of the literature we have identified 14 cases of APL in pregnancy treated with ATRA alone or in combination with chemotherapy. ATRA has been used as early as in the 3rd week of gestation and in no case have malformations or other teratogenic effects occurred. Side-effects, however, ranged from fetal cardiac arrhythmias to induction of labour. Although known to exhibit severe teratogenic effects during the first trimester of pregnancy, ATRA seems to be reasonably safe during the second and third trimesters in the treatment of APL. However, careful obstetric follow-up is mandatory regarding fetal cardiac complications. 相似文献
22.
23.
Katharina Götze Uwe Platzbecker Aristoteles Giagounidis Detlef Haase Michael Lübbert Carlo Aul Arnold Ganser Ulrich Germing Wolf-Karsten Hofmann 《Annals of hematology》2010,89(9):841-850
Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders characterized by ineffective hematopoiesis, peripheral
cytopenias, and a substantial risk of progression to acute myeloid leukemia (AML). For many years, the main treatment option
for MDS was best supportive care which alleviates symptoms, but has no effect on the natural course of the disease. Recently,
demethylating agents have become available as a promising new treatment for patients with MDS. In two randomized clinical
trials, the demethylating agent azacitidine has demonstrated a reduced risk of transformation to AML, improvement of peripheral
blood values, an improved quality of life, and a definite survival advantage compared to conventional care regimens for patients
with International Prognostic Scoring System score of intermediate-2 or high-risk MDS. This review aims to provide practical
recommendations for the use of azacitidine and the management of its side effects in patients with MDS, assuring safe administration
and best efficacy of treatment. 相似文献
24.
Aristotle N Voineskos Jason P Lerch Daniel Felsky Arun Tiwari Tarek K Rajji Dielle Miranda Nancy J Lobaugh Bruce G Pollock Benoit H Mulsant James L Kennedy 《Neuropsychopharmacology》2011,36(9):1871-1878
Schizophrenia and bipolar disorder share genetic risk, brain vulnerability, and clinical symptoms. The ZNF804A risk variant, rs1344706, confers susceptibility for both disorders. This study aimed to identify neural mechanisms common to both schizophrenia and bipolar disorder through this variant''s potential effects on cortical thickness, white matter tract integrity, and cognitive function. Imaging, genetics, and cognitive measures were ascertained in 62 healthy adults aged between 18 and 59 years. High-resolution multimodal MRI/DTI imaging was used to measure cortical thickness and major frontotemporal and interhemispheric white matter tracts. The general linear model was used to examine the influence of the ZNF804A rs1344706 risk variant on cortical thickness, white matter tract integrity, and cognitive measures. Individuals homozygous for the risk variant (‘A'' allele) demonstrated reduced cortical gray matter thickness in the superior temporal gyrus, and in the anterior and posterior cingulate cortices compared with C-allele carriers. No effect of the risk variant on microstructural integrity of white matter tracts was found. Reduced attention control was found in risk allele homozygotes, aligning with findings in the anterior cingulate cortex. Our data provide a novel, genetically based neural risk mechanism for the major psychoses by effects of the ZNF804A risk variant on neural structures and cognitive function susceptible in both disorders. Our findings link genetic, imaging, and cognitive susceptibility relevant to both schizophrenia and bipolar disorder. 相似文献
25.
Bergen SE Balhara YP Christoforou A Cole J Degenhardt F Dempster E Fatjó-Vilas M Khedr Y Lopez LM Lysenko L McGrath LM Mühleisen TW Neves FS Nymberg C Ozomaro U Verweij KJ Voineskos AN Zai CC O'Shea A DeLisi LE 《Psychiatric genetics》2011,21(3):136-172
The XVIIIth World Congress of Psychiatric Genetics, sponsored by The International Society of Psychiatric Genetics took place in Athens, Greece on October 3-7, 2010. Approximately 950 participants gathered to discuss the latest findings in this rapidly advancing field. The following report was written by junior travel awardees, as well as others who were volunteers from student meeting attendees. Each was assigned sessions as rapporteurs. This report represents some of the areas covered in oral presentation during the conference, and reports on some of the notable major new findings described at this 2010 World Congress of Psychiatric Genetics. 相似文献
26.
Daphne Voineskos Vincenzo De Luca Stuart MacGregor Olga Likhodi Laura Miller Aristotle N. Voineskos James L. Kennedy 《Journal of neural transmission (Vienna, Austria : 1996)》2009,116(4):479-486
Genetic vulnerability to psychiatric illness extends across major psychiatric illness. Neuregulin 1 (NRG1) is a large gene
on chromosome 8p, that has been identified as a susceptibility factor in bipolar disorder and schizophrenia. In particular,
a core at risk haplotype has received considerable attention for a putative role in the pathophysiology of the major psychoses
(schizophrenia and bipolar disorder). This core haplotype can be represented by three markers 478B14-848, 420M9-1395, and
SNP8NRG221533. We genotyped 312 families with bipolar probands, and 120 families with schizophrenia probands. Association
of the core haplotype was tested for with age-at-onset and with three phenotypes: major psychosis, schizophrenia, and bipolar
disorder. Neither age of onset (P = 0.893) nor the major psychosis phenotype (P = 0.374) was associated with the core haplotype in the overall sample. Ours was the first study to investigate the NRG1 core
haplotype with age of onset of major psychoses, and despite our preliminary negative findings, this area deserves further
investigation. 相似文献
27.
Germing U Strupp C Knipp S Kuendgen A Giagounidis A Hildebrandt B Aul C Haas R Gattermann N Bennett JM 《Haematologica》2007,92(7):974-977
The WHO classification moved CMML to myeloproliferative/myelodysplastic disorders, and defined CMML I and CMML II according to medullary and peripheral blast count. To confirm these proposals, we analyzed 266 patients with CMML I and 73 patients with CMML II. Median survival time was 20 months for CMML I, and 15 months for CMML II (p<0.005). The cumulative risk of AML evolution differed between patient groups (p=0,001). No conclusive differences in clinical, morphologic, hematologic or cytogenetic parameters were found. These data support the WHO proposals for the classifi-cation of CMML. 相似文献
28.
29.
Knipp S Hildebrand B Kündgen A Giagounidis A Kobbe G Haas R Aul C Gattermann N Germing U 《Cancer》2007,110(2):345-352
BACKGROUND: It is unclear whether intensive chemotherapy is beneficial to patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) if they are aged >/=60 years. METHODS: The authors studied 160 patients with a median age of 67 years who received intensive chemotherapy for MDS or AML with cytosine arabinoside and an anthracycline. RESULTS: At diagnosis, cytogenetic analysis was available in 146 patients. Karyotype was normal in 78 patients and abnormal in 68 patients. Of the abnormal karyotypes, 32 belonged to the high-risk category, ie, they involved either >/=3 chromosomes or chromosome 7. Complete remission (CR) was achieved by 94 patients (56%). CR rates were 70% among the patients who had a normal karyotype, 69% among the patients who had an abnormal (noncomplex) karyotype, but only 46% among the patients ho had a high-risk karyotype. The median survival was 9.5 months in the entire group, 18 months in patients with normal karyotype, 6 months in patients with abnormal, and 4 months in patients with a high-risk karyotype. A poor prognosis was attributable to low rates of CR and a high risk of early recurrence. CONCLUSIONS: According to the current data, elderly patients with AML or advanced MDS do not benefit from intensive chemotherapy if they show karyotype anomalies, especially those in the high-risk category. 相似文献
30.